EUVIMEDEUVIMED entdecken
Crossref

The Effect of Colesevelam on the Microbiome in Postoperative Crohn’s Disease

Aditi Kumar iD, Mohammed Nabil Quraishi, Hafid O Al-Hassi, Mohammed Elasrag, Jonathan P Segal, Manushri Jain, Helen Steed, Jeffrey Butterworth, Adam Farmer, John Mclaughlin, Andrew D Beggs iD, Matthew J Brookes

Inflammatory Bowel Diseases · 10.02.2025 · 31 (2) · 539-551

DOI: 10.1093/ibd/izae230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 18.10.2024. Verfasst von Aditi Kumar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK. Hauptthemen laut MEDLINE: Crohn Disease, Gastrointestinal Microbiome, Colesevelam Hydrochloride, Diarrhea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Bowel and Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While surgery plays a pivotal role in the management of ileal Crohn’s disease, the risk of endoscopic recurrence following an ileocaecal resection can be greater than 65% within 12 months of surgery. More than 90% of patients with Crohn’s disease have a concomitant diagnosis of bile acid diarrhea following an ileal resection. This pilot study aimed to assess whether the use of bile acid sequestrants in patients with Crohn’s disease who have undergone a primary terminal ileal resection with concomitant bile acid diarrhea can alter the microbiome and prevent disease recurrence.

Methods

Patients with Crohn’s disease who underwent a primary terminal ileal resection and had symptoms of diarrhea within 1-3 months of surgery underwent 75SeHCAT testing for bile acid diarrhea. If positive (75SeHCAT ≤ 15%), patients were treated with colesevelam and stool samples were collected at 4 weeks, 8 weeks, and 6-12 months posttreatment. If negative (75SeHCAT > 15%), treatment was not given and were reviewed in the clinic as per local guidelines. All patients underwent a 6-12 month postoperative colonoscopy where further stool samples and mucosal biopsies were taken. Disease activity was established using the endoscopic Rutgeert’s score, with disease remission defined as Rutgeert’s score <i2 and disease recurrence ≥i2. 16S ribosomal RNA gene analysis was undertaken for the collected fecal and mucosal samples to assess α/β-diversity and microbial composition.

Results

A total of 14 patients who completed the study, 10 of whom had a 75SeHCAT positive diagnosis of bile acid diarrhea and were started on treatment with colesevelam. Four patients did not require treatment as 3 were asymptomatic and 1 had a negative 75SeHCAT scan. Three of the fourteen patients had disease recurrence at their 6-12 month postoperative colonoscopy assessment, of which 1 patient was taking colesevelam and 2 patients were not taking colesevelam. A total of 44 fecal samples and 44 mucosal biopsies underwent 16S ribosomal RNA gene analysis to assess α/β-diversity and microbial composition. In the colesevelam treated patients there was no significant difference in α/β-diversity pre- and posttreatment. Pretreatment, the 3 most abundant bacterial classes in all patients were Bacteroidia, Clostridia, and Gammaproteobacteria. Following 6-12 months of treatment, out of the 9 patients on colesevelam, 5/9 (55.6%) had a reduction in Bacteroidia, 9/9 (100%) had an increase in Clostridia, and 7/9 (77.8%) had a reduction in Gammaproteobacteria. Of the 2 patients not given colesevelam, one showed a reduction in Bacteroidia, increase in Clostridia and a reduction in Gammaproteobacteria.

Conclusions

This small pilot study demonstrated that patients who were given colesevelam, were more likely to be in disease remission at their 6-12 months colonoscopy review compared with those not treated. Furthermore, treatment with colesevelam may have a role in altering the microbiome to help maintain remission states in postoperative Crohn’s disease. Larger mechanistic studies are now needed to confirm these findings and demonstrate statistical significance as well as investigate whether this benefit may be present even in those patients with 75SeHCAT negative disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseGastrointestinal MicrobiomeColesevelam HydrochlorideDiarrheaPostoperative ComplicationsHumansFemaleMaleAdultPilot ProjectsMiddle AgedBile Acids and SaltsFecesColonoscopyIleumFollow-Up StudiesRecurrenceYoung AdultRNA, Ribosomal, 16S

Stichwörter der Autor:innen

Crohn’s diseasebile acid diarrhoeabile acid sequestrantscolesevelammicrobiometerminal ileal resection

Substanzen

Colesevelam HydrochlorideBile Acids and SaltsRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
  • University of Birmingham Microbiome Treatment Centre, Birmingham, UK.
  • Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Research Institute in Healthcare Science, University of Wolverhampton, Wolverhampton, UK.
  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Aston Medical School, College of Health and Life Sciences, Aston University, Birmingham, UK.

ORCID-Profile: Aditi Kumar, Andrew D Beggs

Förderung

  • Bowel and Cancer Research

Zitieren

APA

Kumar, A., Quraishi, M. N., Al-Hassi, H. O., Elasrag, M., Segal, J. P., Jain, M., Steed, H., Butterworth, J., Farmer, A., Mclaughlin, J., Beggs, A. D., & Brookes, M. J. (2025). The Effect of Colesevelam on the Microbiome in Postoperative Crohn’s Disease. Inflammatory Bowel Diseases, 31(2), 539-551. https://doi.org/10.1093/ibd/izae230

Vancouver

Kumar A, Quraishi MN, Al-Hassi HO, Elasrag M, Segal JP, Jain M, et al. The Effect of Colesevelam on the Microbiome in Postoperative Crohn’s Disease. Inflammatory Bowel Diseases. 2025;31(2):539-551. doi:10.1093/ibd/izae230

BibTeX
@article{Kumar2025,
  author = {Kumar, Aditi and Quraishi, Mohammed Nabil and Al-Hassi, Hafid O and Elasrag, Mohammed and Segal, Jonathan P and Jain, Manushri and Steed, Helen and Butterworth, Jeffrey and Farmer, Adam and Mclaughlin, John and Beggs, Andrew D and Brookes, Matthew J},
  title = {The Effect of Colesevelam on the Microbiome in Postoperative Crohn’s Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {539--551},
  doi = {10.1093/ibd/izae230}
}
Kostenlos starten →